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South Africa (SA) has the highest number of confirmed positive 
SARS-CoV-2 infections on the African continent, with 1 491 807 
laboratory-confirmed COVID-19 cases and 47 899 COVID-related 
deaths recorded from the first case on 5 March 2020 until 13 February 
2021.[1] Population cohort analysis data from Western Cape Province, 
SA, demonstrated a doubling of COVID-19 mortality risk in persons 
living with HIV.[2] Although more data confirming the interaction 
between COVID-19 and HIV are emerging globally,[3,4] there are 
limited data available for COVID-19 in pregnant women living with 
HIV (PLHIV).[5]
Infection rates for COVID-19 are higher in pregnant women 
than in adults of similar age in the general population.[6] Risk 
factors for severe COVID-19 are well described and are similar for 
pregnant women, including pre-existing comorbidities, advanced 
maternal age and obesity.[7-9] Immunological changes associated 
with pregnancy may also predispose pregnant women to severe 
viral infections, as observed during the 2009 influenza A (H1N1) 
pandemic.[10,11] There is mounting evidence that pregnant women 
with COVID-19 have higher rates of intensive care unit (ICU) 
admission, invasive ventilation and mortality compared with non-
pregnant individuals. [12] Whether concomitant HIV infection in 
pregnancy affects SARS-CoV-2 infection risk, disease severity and 
COVID-19 outcome is currently unknown.
Objectives
In this prospective observational cohort study, we describe women 
with high-risk pregnancies and confirmed COVID-19 presenting 
to a large referral hospital in Cape Town, SA. Our objectives 
were: (i) to describe the clinical presentation and outcomes of 
women with high-risk pregnancies diagnosed with COVID-19; 
(ii) to determine whether risk factors for severe disease and adverse 
outcomes of COVID-19, including the need for respiratory support, 
ICU admission and death, differed in pregnant women without HIV 
compared with PLHIV; and (iii) to compare the number of maternal 
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Background. The impact of SARS-CoV-2 infection in pregnant women living with HIV (PLHIV) has not been described previously.
Objectives. To describe the clinical presentation and outcomes of a cohort of women with high-risk pregnancies with confirmed COVID-
19 to determine whether risk factors for disease severity and adverse outcomes of COVID-19 differed in pregnant women without HIV 
compared with PLHIV.
Methods. We prospectively enrolled pregnant women with COVID-19 attending the high-risk obstetric service at Tygerberg Hospital, Cape 
Town, South Africa, from 1 May to 31 July 2020, with follow-up until 31 October 2020. Women were considered high risk if they required 
specialist care for maternal, neonatal and/or anaesthetic conditions. Common maternal or obstetric conditions included hypertensive 
disorders, morbid obesity (body mass index (BMI) ≥40 kg/m2) and diabetes. Information on demographics, clinical features, and 
maternal and neonatal outcomes was collected and compared for PLHIV v. pregnant women without HIV.
Results. One hundred women (72 without HIV and 28 PLHIV) with high-risk pregnancies had laboratory-confirmed COVID-19. Among 
the 28 PLHIV, the median (interquartile range) CD4 count was 441 (317 - 603) cells/µL, and 19/26 (73%) were virologically suppressed. 
COVID-19 was diagnosed predominantly in the third trimester (81%). Obesity (BMI ≥30 in n=61/81; 75%) and hypertensive disorders 
were frequent comorbidities. Of the 100 women, 40% developed severe or critical COVID-19, 15% required intensive care unit admission 
and 6% needed invasive ventilation. Eight women died, 1 from advanced HIV disease complicated by bacteraemia and urosepsis. The crude 
maternal mortality rate was substantially higher in women with COVID-19 compared with all other deliveries at our institution during this 
period (8/91 (9%) v. 7/4 058 (0.2%); p<0.001). Neonatal outcomes were favourable. No significant differences in COVID-19 risk factors, 
disease severity, and maternal/neonatal outcome were noted for PLHIV v. those without HIV.
Conclusions. In this cohort of high-risk pregnant women, the impact of COVID-19 was severe, significantly increasing maternal mortality 
risk compared with baseline rates. Virally suppressed HIV infection was not associated with worse COVID-19 outcomes in pregnancy.
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deaths, rates of multiple births, caesarean sections and stillbirths, 
and the number of low-birthweight (LBW) infants for COVID-19 




We conducted an observational cohort study of pregnant women 
with COVID-19 who were attending the high-risk obstetric service 
at Tygerberg Hospital (TBH), Cape Town, SA. We included women 
who presented to the service between 1 May and 31 July 2020. 
All pregnant women with laboratory-confirmed positive SARS-
CoV-2 reverse transcriptase-polymerase chain reaction (RT-PCR) 
results during these 3 months were prospectively and consecutively 
included. Women were followed up until 31 October 2020 to allow 
them all to deliver.
Participants
Pregnant women attending the high-risk obstetric care service 
were screened for symptoms and/or signs of COVID-19, or contact 
exposure. Only women who screened positive for symptoms had 
nasopharyngeal swab tests submitted for SARS-CoV-2 RT-PCR, 
as testing capacity was limited. We also included women whose 
symptoms and/or positive SARS-CoV-2 test result occurred within 
7  days of delivery, as it was likely that they had contracted SARS-
CoV-2 infection during pregnancy. All women who had symptoms 
and/or a positive test >7 days post partum were excluded.
Study setting
TBH is the largest public sector referral hospital in Cape Town. The 
obstetric service delivers >8 000 women a year and only manages 
high-risk pregnancies. The caesarean section rate (48%) and LBW 
rate (39%) at TBH are both high.[13] Common high-risk maternal or 
obstetric conditions include hypertensive disorders, morbid obesity 
(body mass index (BMI) ≥40 kg/m2) and diabetes.[14] According to 
SA referral guidelines, all women in the referral hospital’s drainage 
area with a BMI ≥40 kg/m2 have to be referred to the referral hospital 
and delivered in the hospital. HIV is not considered a high-risk factor 
in our setting. Testing for HIV is offered to all pregnant women at 
their first antenatal visit and is repeated at 32 weeks’ gestation and at 
delivery, according to national guidelines.[15] With expanded access 
to diagnosis of and treatment for HIV, increasing numbers of women 
are initiated on combination antiretroviral therapy (cART) before 
falling pregnant.[16] Universal cART for all PLHIV was introduced 
in 2015.[16] Approximately 20% of all women who deliver at TBH are 
PLHIV, with an intrauterine HIV transmission rate of 0.82%.[17]
In preparation for the COVID-19 pandemic, a dedicated obstetric 
unit (separate ward, theatres and staff) was established for the care 
of pregnant women with suspected and confirmed COVID-19. This 
unit was staffed by senior obstetric trainees, nursing and midwifery 
teams who were supported by critical care consultants, obstetricians, 
and anaesthetic and neonatology staff. Where possible, healthy 
neonates were kept with their mothers to establish breastfeeding. In 
line with national protocols, SARS-CoV-2 RT-PCR testing was not 
performed for healthy neonates born to mothers with COVID-19. 
If a neonate required admission to any neonatal ward, SARS-CoV-2 
testing was performed.
Data collection and classification
The obstetric trainee team and research midwife prospectively 
collected routine clinical data and laboratory outcomes on all 
pregnant women with confirmed COVID-19. Data included 
demographics, HIV information, COVID-19 symptoms, pregnancy 
complications, and birth and neonatal outcomes. Data on the number 
of deliveries, the route of delivery and maternal/neonatal outcome 
are routinely captured on an electronic birth register at TBH. Data 
for the patients with COVID-19 were collected using a secure online 
Research Electronic Data Capture (REDCap) data registry hosted by 
Stellenbosch University.[18,19] Ethical approval was obtained from the 
Stellenbosch University Health Research Ethics Committee (ref. no. 
N20/04/002_COVID-19).
BMI was corrected for the trimester when first weight measurements 
were taken, to adjust for expected weight gain during pregnancy as 
per provincial policy. If measured in the second trimester, 4 kg was 
deducted, and in the third trimester, 8 kg was deducted. A miscarriage 
was defined as the accidental loss of a fetus before 24 weeks’ 
gestation.[20] COVID-19 severity (mild/moderate v. severe/critical) 
was classified using the National Institutes of Health criteria. [21] Mild 
or moderate illness was defined as symptomatic women not needing 
oxygen supplementation, while women with respiratory symptoms 
requiring oxygen supplementation were defined as having severe 
illness. Critical illness included respiratory failure, septic shock, and/
or multiorgan dysfunction.
Statistical analysis
Descriptive analysis was conducted reporting counts and proportions. 
Non-parametric data were described using medians and interquartile 
ranges (IQRs). Pregnant women with COVID-19 were analysed by 
HIV status. Mild or moderate COVID-19 was compared with severe 
or critical COVID-19. Student’s t-test or the Mann-Whitney U-test 
was used for comparing continuous data, and the χ2 test or Fisher’s 
exact test was used for comparing categorical data. A p-value <0.05 
was considered statistically significant.
Results
SARS-CoV-2 laboratory testing of high-risk  
pregnant women
SARS-CoV-2 RT-PCR testing was performed in 275 women atten-
ding the high-risk obstetric service between 1 May and 31 July 2020. 
COVID-19 was confirmed in 103/275 women (37%), of whom 3 were 
excluded because their COVID-19 symptoms started >7 days post 
partum. The final cohort of 100 pregnant women was followed up 
until 31 October 2020 to allow all of them to deliver.
Pre-existing medical and obstetric conditions in  
women with COVID-19
Seventy-two of the 100 pregnant women with COVID-19 were 
HIV-uninfected and 28 were PLHIV (Table 1). Twenty-seven of 
28 PLHIV (96%) were receiving cART at the time of delivery. CD4 
counts were available for 21/28 women (75%) (median (IQR) 441 
(317 - 603) cells/µL), and 19/26 (73%) were virologically suppressed 
(HIV viral load <50 copies/mL). For the 7 PLHIV with a detectable 
HIV viral load, the median (IQR) viral load was 361 (104 - 461) 
copies/mL. The viral load was not available for 2 women. PLHIV 
were more likely to be older and multiparous compared with 
women without HIV. Obesity was a frequent comorbidity (weights 
available for 81/100), with 25/81 (31%) obese and 36/81 (44%) 
morbidly obese women; no difference was observed between 
PLHIV and women without HIV. Pre-existing chronic hypertension 
and diabetes mellitus were present in 22/100 and 6/100 women, 
respectively, and 9/100 women had a previous or current diagnosis 
of tuberculosis.
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Table 1. Demographics, COVID-19 and pregnancy outcomes by HIV status
All women (N=100) Without HIV (N=72) With HIV (N=28) p-value
Demographics
Age (years), median (IQR) 31 (27 - 37) 31 (27 - 36) 34 (28 - 39) 0.082
BMI (kg/m2),* n (%)
<25 (normal weight) 8/81 (10) 6/59 (10) 2/22 (9) 0.603
≥25 - <30 (overweight) 12/81 (15) 9/59 (15) 3/22 (14) 0.554
≥30 - <40 (obese) 25/81 (31) 16/59 (27) 9/22 (41) 0.304
≥40 (morbidly obese) 36/81 (44) 28/59 (48) 8/22 (36) 0.334
Multiparous, n (%) 78 (78) 51 (71) 27 (96) 0.006
Twin pregnancy, n (%) 5 (5) 5 (7) 0 (0) 0.186
Chronic hypertension, n (%) 22 (22) 19 (26) 3 (11) 0.089
Gestational hypertension, n (%) 18 (18) 13 (18) 5 (18) 0.981
Pre-eclampsia, n (%) 24 (24) 18 (25) 6 (21) 0.733
Diabetes mellitus, n (%) 6 (6) 4 (6) 2 (7) n/a
Gestational diabetes, n (%) 14 (14) 12 (17) 2 (7) 0.183
Asthma, n (%) 4 (4) 4 (6) (0) n/a
Tuberculosis (current and previous), n (%) 9 (9) 5 (7) 4 (14) n/a
Anaemia,† n (%) 28 (28) 17 (24) 11 (39) 0.117
COVID-19 
Timing of infection, n (%)
1st trimester 2 (2) 1 (1) 1 (4) n/a
2nd trimester 17 (17) 13 (18) 4 (14) 0.451
3rd trimester 81 (81) 58 (81) 23 (82) 0.856
Delivery within 2 weeks of diagnosis, n (%) 50 (50) 33 (46) 17 (61) 0.181
Symptoms
Cough, n (%) 77 (77) 56 (78) 21 (75) 0.767
Dyspnoea, n (%) 49 (49) 35 (49) 14 (50) 0.901
Fever, n (%) 36 (36) 26 (36) 10 (36) 0.970
Duration of symptoms (days), median (IQR) 3 (2 - 5) 3 (2 - 4) 3 (1 - 6) n/a
Disease severity, n (%)
Mild 60 (60) 43 (60) 17 (61) 0.928
Severe 29 (29) 20 (28) 9 (32) 0.666
Critical 11 (11) 9 (12) 2 (7) n/a
Maximum respiratory support, n (%)
Nasal prong oxygen 16/40 (40) 12/29 (42) 4/11 (36) 0.533
Face mask oxygen/non-rebreather mask 13/40 (33) 9/29 (31) 4/11 (36) 0.514
High-flow oxygen/nCPAP 5/40 (12) 3/29 (10) 2/11 (19) 0.422
Invasive ventilation 6/40 (15) 5/29 (17) 1/11 (9) 0.464
Treatments, n (%)
Thromboprophylaxis 59 (59) 39 (54) 20 (71) 0.115
Dexamethasone‡ 13 (13) 7 (10) 6 (22) 0.111
Hydrocortisone 3 (3) 3 (4) 0 n/a
Methylprednisolone 1 (1) 1 (1) 0 n/a
Antibiotics§ 55 (55) 38 (53) 17 (61) 0.474
Complications
Thromboembolism, n (%) 4 (4) 2 (3) 2 (2) n/a
Acute kidney injury,¶ n (%) 3 (3) 2 (3) 1 (4) n/a
ICU admission, n (%) 15 (15) 9 (13) 6 (21) 0.206
ICU stay (days), median (IQR) 4 (3 - 10) 5 (4 - 10) 3 (1 - 6) 0.271
Pregnancy outcomes, n (%)
Caesarean section 49 (49) 30 (42) 19 (68) 0.019
Vaginal delivery with live birth 37 (37) 32 (44) 5 (18) 0.013
Stillbirth 5 (5) 3 (4) 2 (7) n/a
Medical termination of pregnancy 1 (1) 1 (4) 0 n/a
Miscarriage 4 (4) 3 (4) 1 (4) n/a
Mother died with fetus in utero 2 (2) 2 (3) 0 n/a
Unknown 2 (2) 2 (3) 0 n/a
Spontaneous preterm labour <37 weeks 4 (4) 3 (4) 1 (4) n/a
Placental abruption 2 (2) 2 (3) 0 n/a
Maternal death 8 (8) 6 (8) 2 (7) n/a
IQR = interquartile range; BMI = body mass index; nCPAP = nasal continuous positive airway pressure; ICU = intensive care unit; n/a = not applicable.
*Data only available for 81 women.
†Haemoglobin <11 g/dL.
‡For patients receiving oxygen therapy, dexamethasone was added as standard of care from 17 June 2020.
§Antibiotics (N=55): ceftriaxone n=44, ampicillin n=1, amoxicillin/clavulanic acid n=6, azithromycin n=1, cephazolin n=1.
¶Abrupt reduction in renal function based on an elevation of serum creatinine 2 - 3-fold from baseline.[29]
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COVID-19 in 100 women with high-risk pregnancies
Fourteen women were managed as outpatients and 86 required 
hospital admission. Common symptoms included cough (77%), 
dyspnoea (49%) and fever (36%). Of the 86 admissions, 46 (53%) were 
for COVID-19-related illness, 23 (27%) for delivery, and 17 (20%) for 
other obstetric indications. The median hospital stay was 4 days (range 
1 - 25). COVID-19 was diagnosed mainly in the third trimester (81%), 
and half of all women delivered within 2 weeks of infection onset.
Sixty women had mild/moderate COVID-19, 29 had severe disease 
and 11 had critical disease. Of the 11 women with critical disease, 6 
were ventilated for respiratory failure and 1 collapsed and died in 
the ward prior to ICU admission. The remaining 4 did not require 
ventilation but presented with multiorgan dysfunction in addition 
to COVID-19 pneumonia: 1 with cardiomyopathy needing inotropic 
support, 1 with glucose instability requiring an insulin infusion, 1 
with delirium, and 1 with bacteraemia and urosepsis.
Of the 30/40 women in the severe/critical disease categories whose 
weight was documented, all were either overweight (3/30; 10%), 
obese (9/30; 30%) or morbidly obese (18/30; 60%). No difference 
in proportions was observed between PLHIV with mild/moderate 
disease compared with PLHIV with severe/critical disease (n=17/60 
(28%) v. 11/40 (28%); p=0.928). Dyspnoea was more common in 
the severe or critical disease group compared with mild or moderate 
disease (33/40 (83%) v. 16/60 (27%); p=0.001).
Women with severe/critical disease were also more likely to need 
other supportive treatment including anticoagulation (32/40; 80%), 
dexamethasone (13/40; 33%) and broad-spectrum antibiotics (29/40; 
73%). Fifteen women required admission to the ICU or the maternity 
critical care unit, 12 primarily for respiratory support and 3 for non-
COVID-19-related conditions (diabetic ketoacidosis, a caesarean 
hysterectomy, and severe pre-eclampsia).
No differences between PLHIV and women without HIV were found 
with regard to the timing of infection, type and duration of symptoms, 
disease severity, need for respiratory support, other medical treatment, 
or complications. Pregnancy outcomes for the 100 women (5 twin 
pregnancies) included 91 live births, 5 stillbirths, 4 miscarriages, 2 
women who died with the fetus in utero and 1 medical termination of 
pregnancy. The 2 women who died with the fetus in utero died from 
complications of COVID-19. The medical termination was for severe 
preterm pre-eclampsia. There were 3 first-trimester miscarriages, and 
1 at 19 weeks due to diabetic ketoacidosis. One baby was stillborn to 
a mother who defaulted her cART, 2 stillbirths were associated with 
severe pre-eclampsia, 1 was due to a placental abruption without 
associated pre-eclampsia, and the 5th was in a woman who had severe 
hypoxia related to COVID-19. Birth outcomes were unknown for 
2 women who were lost to follow-up. No differences were observed 
for pregnancy outcomes in terms of HIV status, except for a higher 
caesarean section rate in older, multiparous PLHIV, where 9/19 (47%) 
had a history of two previous caesarean sections.
Maternal mortality
Eight women in this cohort died, of whom 2 were PLHIV. One 
woman died from advanced HIV and 7 from complications related 
to COVID-19 (Table 2). The woman with advanced HIV had a CD4 
count of 14 cells/µL and had defaulted her cART in 2018. She had not 
received any antenatal care and delivered a macerated fetus weighing 
1 131 g. She was diagnosed with Escherichia coli septicaemia, cultured 
in both blood and urine samples, and died 8 days later from urosepsis 
and acute renal failure. Her GeneXpert test for tuberculosis was also 
positive. The other PLHIV had a suppressed viral load and no clinical 
indications of advanced HIV disease.
Weight and height measurements were available for 6 of the 7 
women whose deaths were directly related to COVID-19. One 
woman was overweight, and the others were all obese. Five women 
had chronic hypertension, and 2 of these women developed severe 
pre-eclampsia. Two women had pregnancies complicated by type 2 
diabetes mellitus. Two women died with the fetus in situ. One woman 
had a caesarean section for severe pre-eclampsia and developed 
COVID-19 symptoms post partum. Four women needed a caesarean 
section delivery to improve respiratory function. One neonate was 
delivered close to term and 2 were delivered preterm. One woman 
who was delivered to improve her respiratory function had a neonatal 
death related to intrauterine hypoxia.
Neonatal outcomes
Among the 91 liveborn neonates (66 in women without HIV and 25 
in PLHIV), the median (IQR) gestational age at delivery was 38 (36 - 
39) weeks (Table 3). Twenty-seven infants (30%) were preterm and 
25 (28%) were LBW. Of the 91 liveborn neonates, 76 (84%) remained 
with their mother and 15 (16%) were admitted to a neonatal ward; 
the median (IQR) gestational age of admitted infants was 34 (26 - 
38) weeks. Reasons for admission included diagnoses of respiratory 
distress syndrome in 9, transient tachypnoea of the newborn in 
2, congenital pneumonia in 2, jaundice, hypoglycaemia, and 1 
neonate with an imperforate anus who required surgery. Of these 
15 admitted neonates, 14 required respiratory support, including 
invasive ventilation in 1, nasal continuous positive airway pressure 
ventilation in 12 and nasal cannula oxygen in 1. The neonatal stay 
ranged from 5 to 30 days. A SARS-CoV-2 test was negative in 13/15 
admitted neonates within 72 hours after birth (invalid in 1 and 
not done in another). No differences in neonatal birthweight or 
outcome were observed between neonates born to women without 
HIV v. PLHIV. The neonatal outcomes of the mothers who died of 
COVID-19 were poor. There were 4 intrauterine fetal deaths and 
1 early neonatal loss in a neonate who had no respiratory effort at 
birth. There were 2  preterm deliveries, one at 32 weeks’ gestation 
with a 1  945 g neonate and another at 26 weeks with a neonate 
weighing 750 g (Table 2). The outcome for the 91 liveborn neonates 
was excellent except for the neonate described above whose mother 
also died.
Key obstetric indicators for pregnancies at TBH affected 
and unaffected by COVID-19 (1 May - 31 October 2020)
A total of 4 149 women with high-risk pregnancies were delivered 
at TBH during this time frame, 91 with COVID-19 (9 from the 
cohort delivered at other institutions) and 4 058 not included in the 
study cohort. No differences were observed in the rates of multiple 
pregnancy, caesarean section, stillbirth and live LBW infants, but the 
crude maternal mortality rate was substantially increased in women 
with COVID-19 compared with women without suspected COVID-
19 (n=8/91 (8.8%) v. n=7/4 058 (0.2%); p<0.001) (Fig. 1).
Discussion
Our observational study is the first to assess the impact of laboratory-
confirmed COVID-19 in a cohort of high-risk pregnant women 
from sub-Saharan Africa, including women living with HIV. Of 
the 28 PLHIV (a quarter of the total cohort), the majority were 
receiving cART and were virally suppressed. In this group of high-
risk pregnancies with well-controlled HIV disease, we found no 
differences in COVID-19 risk factors, disease severity or outcomes 
for both mothers and their neonates, compared with COVID-19 
pregnant women without HIV infection.
1178       December 2021, Vol. 111, No. 12
RESEARCH




(kg/m2) Other risk factors Delivery Neonatal outcome Maternal outcome Death
























































35 5 4 39 Chronic 
hypertension
Asthma












38 6 5 40 Chronic 
hypertension




Day 4 after 
admission





























Day 4 after 
admission













BMI = body mass index; cART = combined antiretroviral therapy; TB = tuberculosis; CS = caesarean section; NICU = neonatal intensive care unit; DM = diabetes mellitus;  
PLHIV = pregnant woman living with HIV.
Table 3. Demographics and outcome of live births to women with COVID-19
Neonatal outcomes Live births (N=91) Not exposed to HIV (N=66) Exposed to HIV (N=25) p-value
Gestation at delivery (weeks), median (IQR) 38 (36 - 39) 38 (36 - 39) 39 (38 - 39) 0.123
Delivered before 37 weeks, n (%) 27 (30) 21 (32) 6 (24) 0.466
Birth weight (g), median (IQR) 3 085 (2 350 - 3 520) 3 010 (2 380 - 3 475) 3 300 (2 350 - 3 545) 0.475
Low birthweight (<2 500 g), n (%) 25 (28) 18 (27) 7 (28) 0.945
Male, n (%)* 44/86 (51) 29/61 (48) 15/25 (60) 0.058
Neonatal ward admission, n (%) 15 (16) 11 (17) 4 (16) 0.606
Infant feeding, n (%)
Exclusive breastfeeding 48 (53) 33 (50) 15 (60) 0.394
Exclusive formula feeding 8 (9) 4 (6) 4 (16) n/a
Mixed feeding 4 (4) 4 (6) 0 n/a
Unknown 31 (34) 25 (38) 6 (24) 0.212
Neonatal death 1 (1) 1 (2) 0 n/a
IQR = interquartile range; n/a = not applicable.
*Sex unknown for 5 neonates.
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Of the cohort of 100 pregnant women with 
COVID-19, most were overweight or obese 
and many had underlying risk factors for 
severe COVID-19, including hypertension 
and diabetes mellitus. Risk factors for severe 
and critical disease in pregnant women 
with COVID-19 are simi lar to those in non-
pregnant populations. [22] Severe COVID-19 
in pregnancy has been associated with high 
BMI (odds ratio 2.38; 95% CI 1.67 - 3.39; 
three studies, 877 women).[7] In our study, 
90% of the 40 women who developed 
severe/critical COVID-19 were either obese 
or morbidly obese. The high proportion of 
our cohort that developed severe/critical 
COVID-19 exceeds previous reports,[23] but 
the finding is not surprising, because our 
institution serves as a referral centre for 
severely ill patients and manages high-risk 
pregnancies, and only symptomatic women 
were tested.
Accumulating evidence demonstrates 
that pregnant women with COVID-19 are 
more likely to need admission to an ICU 
and require invasive ventilation than non-
pregnant women of reproductive age with 
COVID-19.[7,24] Fifteen women in our cohort 
required ICU admission, with 6 needing 
intubation and ventilation for impending 
hypoxaemic respiratory failure. The 
crude maternal mortality rate in pregnant 
women with confirmed COVID-19 was 
44 times higher than that for pregnant 
women not suspected to have COVID-19 
during the same period. Rates of multiple 
pregnancies, caesarean sections, stillbirths 
and LBW were unaffected by COVID-19. 
The high mortality rate in our cohort (9%) 
contrasts with outcomes of 462 pregnant 
women with COVID-19 in 10 New York 
hospitals, where the crude mortality rate 
was 0.4% (n=2/462). [25] Of women admitted 
to ICUs in this US cohort, 50% had no 
comorbidities. Before the emergence of 
COVID-19, maternal mortality rates in low- 
to middle-income countries substantially 
exceeded those in high-income countries, 
but the disparity in maternal outcomes by 
region has again been highlighted by the 
pandemic.[26]
Preterm birth rates of between 12.6% and 
17% have been documented in women with 
COVID-19.[7,24] The overall preterm birth rate 
in our cohort was high (30%), but it is similar 
to that for our high-risk obstetric unit. No 
difference was observed between rates of LBW 
in women with COVID-19 v. women without. 
In contrast to many other studies, where 
a quarter of all neonates born to mothers 
with COVID-19 were admitted to a neonatal 
ward,[7] the majority of our neonates (84%) 
remained in the care of their mothers. Only 
16% were admitted to the neonatal ward, 
mainly owing to complications of prematurity. 
No perinatal COVID-19 transmission was 
documented in the few neonates admitted 
to the neonatal ICU, in support of other 
literature showing that perinatal COVID-19 
transmission is rare.[8]
Study strengths and limitations
To our knowledge, this is the first observational 
cohort from Africa to report on COVID-
19 in high-risk pregnant women including 
PLHIV. It adds important information to aid 
in the management of PLHIV with COVID-
19. SA has 7.7 million people living with 
HIV, with ~4.7 million on cART.[27] Further 
studies are needed to fully assess the impact of 
COVID-19 on PLHIV. The impact on PLHIV 
who are newly diagnosed and not virally 
suppressed also needs further investigation. 
SA has reported many COVID-19 cases, 
owing to a high burden of disease and good 
laboratory access for testing. Unfortunately, 
the spread of the disease elsewhere in Africa 
has been less well characterised, with only a 
few small observational studies documenting 
the effect of COVID-19 on African pregnant 
women.[28] Etti et al.[5] plan to address some 
of these knowledge gaps by screening 
>50 000 pregnant women from five sub-
Saharan countries, which will provide more 
information on the burden of COVID-19 in 
pregnant women on the continent.
We acknowledge the following limitations 
of the study. TBH only manages high-
risk pregnancies, and these results are not 
generalisable to all pregnant women. The 
high proportion of pregnant women with 
a BMI ≥40 kg/m2 may have contributed 
to a higher proportion of severe COVID-
19. The numbers are relatively small in 
some subanalyses, and results should be 
interpreted with caution. Information 
regarding the date of HIV diagnosis, staging 
of HIV disease, and type and duration of 
cART was not available. As the majority of 
our PLHIV cohort were virally suppressed, 
we could only assess the impact of COVID-
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Fig. 1. Key obstetric indicators for women with COVID-19 v. all other women pregnant delivering at 
Tygerberg Hospital but not included in the study cohort, 1 May - 31 October 2020. (*Two pregnant 
women who died of COVID-19 did not meet the inclusion criteria for this study: one was >7 days post 
partum, and the other, who was 8 weeks pregnant, was never managed by the obstetric team. These 
women were added to the numerator for calculation of maternal deaths of women not included in the 
study cohort.)
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Conclusions
In this cohort of high-risk pregnant women with COVID-19, 
the impact of the disease in pregnancy was severe; however, no 
clinical differences in outcome attributable to virally suppressed HIV 
infection were noted. We observed a high maternal mortality rate 
with poor outcomes for mother and fetus in women who developed 
critical COVID-19, compared with our institution’s baseline non-
COVID-19-associated maternal mortality rate. Despite these 
pregnant women being very ill, all but one of the liveborn neonates 
survived to hospital discharge.
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